| 
			
			 "COMCO suspects that manufacturers and distributors of the active 
			pharmaceutical ingredient Scopolamine Butylbromide have concluded 
			unlawful price and market sharing agreements," the agency said. 
			"There are reasonable grounds to suspect that the undertakings have 
			kept the prices of this pharmaceutical ingredient high and that they 
			have allocated markets. The investigation shall examine whether 
			there are indeed unlawful restrictions of competition." 
			
			 
			
            [to top of second column] | 
            
			 
			COMCO declined to name the makers of the drug ingredients, but said 
			domestic and foreign companies were under scrutiny.
 (Reporting by John Miller)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |